ImmPACT Bio

Despite significant fundraising results to date, Lyell Immunopharma has been stuck in neutral with its own cancer cell therapy efforts, and the firm revealed on 24 October that it is merging with priv

Merck & Co., Inc. is getting into the well-trodden space of bispecific antibodies by acquiring CN201, a CD19xCD3-directed candidate, from a Chinese biotech company. The Rahway, NJ-based drug maker sa

Smaller biopharma companies will have a chance to shine at this year’s European Hematology Association congress, with Cargo Therapeutics and Kymera among those already picked out by analysts as ones

Zenas BioPharma is ahead of the pack compared with most companies advancing CD19-targeting therapeutics for autoimmune diseases, with plans to report Phase III results in IgG4-related disease and Pha